30 April 2010 - GEST’s key sponsors will be running a series of symposia set to equip delegates with the latest informationabout what’s hot and what’s not in the world of embolization materials.From Thursday 6 May to Saturday 8 May, sessions will be run by Celonova, Biocompatibles, Terumo, Siemens, Cook Medical, Boston Scientific, Biosphere Medical, AGA Medical and Philips.

Breakfast and evening symposia sessions last 30 minutes each.

Lunchtime symposia last 45 minutes each with lunch provided.

Thursday 6 May
12:00
TERUMO (Plenary Hall)

• Watertight Occlusion of the Gastroduodenal Artery
• AZUR in the periphery: The MUSC Experience
• The Use of Hydrogel Coated Coils in the Periphery: The North Shore Medical Center Experience

12:45
CELONOVA (Plenary Hall)
Innovations and Challenges: The Future of Embolization

• UAE with Embozene™ Color-Advanced Microspheres 500 μm in Adenomyosis: MR and clinical follow-up
• Hemoptysis: preliminary results of embolization with Embozene™ Color-Advanced Microspheres and case study
• Embolization therapy: What we know and don’t know, and how (I think) we can know (better)

5:35
BIOCOMPATIBLES (Plenary Hall)
New Horizons in DC Bead® and LC BeadTM Treatment of HCC

• Assessment of Correlation of Response to DC Bead Doxorubicin, in Explanted Liver in Patients with HCC Listed for Orthotopic Liver Transplantation
• The Safety of Combining Systemic Targeted Therapy (Sorafenib) with LC Bead Doxorubicin in Patients with Unresectable HCC

5:35
SIEMENS (Olympic Room)
Image-guided Solutions for Interventional Oncology. Minimally Invasive, Maximally Effective

• Advanced applications for embolizations and need guidance
• New approaches in minimally invasive tumor treatment

Friday 7 May

7:00
BOSTON SCIENTIFIC (Plenary Hall)
Meeting the Embolotherapy Challenge

• Advancing Embolotherapy with the InterlockTM Fibered IDCIM Occlusion System Charles

12:00
COOK MEDICAL (Plenary Hall)

• Health Care Reform and Its Impact on the Global Economy

12:45
BIOSPHERE MEDICAL (Plenary Hall)
Clinical Updates and case studies in liver tumor treatment

• TAE with HepaSphere™ Microspheres
• Lessons Learned with QuadraSphere® Microspheres
• Phase II Study of cTACE and bevacizumab for unresectable HCC
• Irinotecan-HepaSphere TACE: Case studies in Metastatic Colorectal Cancer

5:35
PHILIPS (Concordia Room)
Clinical Experience and Future Directions of MR-HIFU

5:35
AGA MEDICAL (Olympic Room)
International Experience with the New AMPLATZER Vascular Plug 4

• Challenging Visceral Cases Treated with AVP 4
• The Value of AVP 4 in PAVM Indications

Saturday 8 May

12:00
SIRTEX (Plenary Hall)
Clinical Update on Radioembolization: Improving the Outcomes for Patients with Primary or Secondary Liver
Tumors

• Radioembolization of CRC liver metastases: Where are we now and where are we going?
• Radioembolization of HCC: Which patients?

12:45
AGA MEDICAL (Plenary Hall)
Clinical Applications of the AMPLATZER Vascular Plug Family

• Plugs vs Coils: Reducing Procedure Times and Radiation Exposure
• Vascular Plug Family Superiority in the Pelvis